Critical regulation of genes for tumor cell migration by AP-1

Clinical and Experimental Metastasis

Volumn 21, Issue 4, 2004, Pages 293-304

  Bahassi, El Mustapha ^a   Karyala, Saikumar ^b   Tomlinson, Craig R ^b   Sartor, Maureen A ^b   Medvedovic, Mario ^b   Hennigan, Robert F ^a  

^a Dept Environ Hlth Ctr E ^*  (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

AP 1; CapG; metastasis; motility; TSLC 1

Indexed keywords

TRANSCRIPTION FACTOR AP 1;

ARTICLE; CANCER INVASION; CELL CYCLE G1 PHASE; CELL MIGRATION; CELL MOTILITY; CHEMOTAXIS; DNA MICROARRAY; GENE CONTROL; GENE EXPRESSION; HUMAN; HUMAN CELL; METASTASIS; MOLECULAR DYNAMICS; NUCLEOTIDE SEQUENCE; REGULATORY MECHANISM;

CELL LINE, TUMOR; CELL MOVEMENT; CHEMOTAXIS; FIBROSARCOMA; G1 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOGLOBULINS; MEMBRANE PROTEINS; MICROFILAMENT PROTEINS; NUCLEAR PROTEINS; PEPTIDE FRAGMENTS; PROTO-ONCOGENE PROTEINS C-JUN; TRANSCRIPTION FACTOR AP-1; TUMOR SUPPRESSOR PROTEINS;

EID: 7244220141     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:CLIN.0000046132.46946.dd     Document Type: Article

References (50)

1. Hanahan D, Weinberg RA. Hallmarks of cancer. Cell 2000; 100: 57-70.
2. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation. Cell 1991; 64: 327-36.
3. Rajan R, Vanderslice R, Kapur S et al. Epidermal growth factor promotes chemomigration of a human prostate tumor cell line, and EGF immunoreactive proteins are present at sites of metastasis in the stroma of lymph nodes and medullary bone. Prostate 1996; 28: 1-9.
4. Karin M, Liu Z, Zandi E. AP-1 Function and Regulation. Curr Op Cell Biol 1997; 9: 240-6.
5. Curran T, Franza Jr. BR Fos and Jun: The AP-1 Connection. Cell 1988; 55: 395-7.
6. Pulverer BJ, Kyriakis JM, Avruch J et al. Phosphorylation of c-jun mediated by MAP kinases. Nature 1991; 353: 670-1.
7. Miner JM, Yamamoto KR. The basic region of AP-1 specifies glucocorticoid receptor activity at a composite response element. Genes Devel 1992; 6: 2491-501.
8. Bassunk AG, Leiden JM. A Direct physical interaction between ETS and AP-1 transcription factors in normal human T cells. Immunity 1995; 3: 223-37.
9. Liberati NT, Datto MB, Frederick JP et al. Smads bind directly to the jun family of AP-1 transcription factors. Proc Natl Acad Sci USA 1999; 96: 4844-9.
10. Sheshedini L, Knauthe R, Sassone-Corsi P et al. Cell specific inhibitory and stimulatory effects of fos and jun on transcription activation by nuclear receptors. EMBO 1991; 10: 3839-19.
11. Kardassis D, Papakosta P, Pardali K, Moustakas A. c-jun transactivates the promoter of the human p21WAF1/Cip1 gene by acting as a superactivator of the ubiquitous transcription factor Sp1. J Biol Chem 1999; 274: 29572-81.
12. Kovary K, Bravo R. The jun and fos families are both required for cell cycle progression in fibroblasts. Mol Cell Biol 1991; 11: 4466-72.
13. Ledwith BJ, Manam S, Kraynak AR et al. Antisense-fos RNA causes partial reversion of the transformed phenotypes induced by the c-Ha-Ras oncogene. Mol Cell Biol 1990; 10: 1545-55.
14. Ozanne BW, McGarry L, Spence HJ et al. Transcriptional regulation of cell invasion: AP-1 regulation of a multigenic invasion programme. Eur J Cancer 2000; 36: 1640-8.
15. Hennigan RF, Hawker KL, Ozanne BW. Fos-transformation activates genes associated with invasion. Oncogene 1994; 9: 3591-600.
16. Lamb RF, Hennigan RF, Turnbull K et al. AP-1 Mediated invasion requires increased expression of the hyaluronan receptor CD44. Mol Cell Biol 1997; 17: 963-76.
17. Spence HJ, Johnston I, Ewart K et al. Krp1, a novel kelch related protein that is involved in pseudopod elongation in transformed cells. Oncogene 2000; 19: 1266-76.
18. Lamb RF, Ozanne BW, Roy C et al. Essential functional of ezrin in maintainance of cell shape and lamellipodial extension in normal and transformed fibroblasts. Curr Biol 1997; 7: 682-8.
19. Johnston IM, Spence HJ, Winnie JN et al. Regulation of a multigenic invasion programme by the transcription factor, AP-1: Re-expression of a down-regulated gene, TSC-36, inhibits invasion. Oncogene 2000; 19: 5348-58.
20. Bos TJ, Margiotta P, Bush L, Wasilenko W. Enhanced cell motility and invasion of chicken embryo fibroblasts in response to Jun overexpression. Int J Cancer 1999; 81: 404-10.
21. Rinehart-Kim J, Johnston M, Birrer M, Bos T. Alterations in the gene expression profile of MCF-7 breast tumor cells in response to c-Jun. Int. J. Cancer 2000; 88: 180-90.
22. Reichmann E, Schwarz H, Deiner EM et al. Activation of an inducible c-FosER fusion protein causes loss of epithelial polarity and triggers epitheliai-fibroblastoid cell conversion. Cell 1992; 71: 1103-16.
23. Fialka I, Schwarz H, Reichmann E et al. The estrogen-dependent c-JunER protein causes a reversible loss of mammary epithelial cell polarity involving a destabilization of adherens junctions. J Cell Biol 1996; 132: 1115-32.
24. Kustikova O, Kramerov D, Grigorian M et al. Fra-1 induces morphological transformation and increases in vitro invasiveness and motility of epithelioid adenocarcinoma cells. Mol Cell Biol 1998; 18: 7095-105.
25. Rasheed S, Nelson-Rees WA, Toth EM et al. Characterization of a newly derived human sarcoma cell line (HT-1080). Cancer 1974; 33: 1027-33.
26. Tanaka K, Iwamoto Y, Ito Y et al. Cyclic AMP regulated synthesis of the tissue inhibitors of metalloproteinases suppresses the invasive potential of the human fibrosarcoma cell line HT1080. Cancer Res 1995; 55: 2927-35.
27. Paterson H, Reeves R, Brown R et al. Activated N-ras controls the transformed phenotype of HT1080 human fibrosarcoma cells. Cell 1987; 51: 803-12.
28. Gupta S, Stuffrein S, Plattner R et al. Role of phosphoinositide 3-kinase in the aggressive tumor growth of HT1080 human fibrosarcoma cells. Mol Cell Biol 2001; 21: 5846-56.
29. Gupta S, Plattner R, Der CJ, Stanbridge EJ. Dissection of Ras-dependent signaling pathways controlling aggressive tumor growth of human fibrosarcoma cells: Evidence for a potential novel pathway. Mol Cell Biol 2000; 20: 9294-306.
30. Anderson MJ, Casey G, Fasching CL, Stanbridge EJ. Evidence that wild-type TP53, and not genes on either chromosome 1 or 11, controls the tumorigenic phenotype of the human fibrosarcoma HT1080. Genes Chromosomes Cancer 1994; 9: 266-81.
31. Silletti S, Raz A. Autocrine motility factor is a growth factor. Biochem Biophys Res Commun 1993; 194: 446-57.
32. Hennigan RF, Stambrook PJ. Dominant negative c-jun inhibits activation of the cyclin D1 and cyclin E complexes. Mol Biol Cell 2001; 12: 2352-63.
33. Dudoit S, Yang Y, Callow MJ, Speed TJ. Statistical methods for identifying differentially expressed genes in replicated cDNA microarray experiments. Statistica Sinica 2002; 12: 111-39.
34. Littell RC, Milliken GA, Stroup WW, Wolfinger R. SAS system for mixed models. Carey, North Carolina: SAS Institute 1996.
35. Wolfinger RD, Gibson G, Wolfinger ED et al. Assessing gene significance from cDNA microarray expression data via mixed models. J Comput Biol 2001; 8: 625-37.
36. Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc 1995: B57: 289-300.
37. Kramer RH, Bensch KG, Wong J. Invasion of reconstituted basement membrane matrix by metastatic human tumor cells. Cancer Res 1986; 46: 1980-9.
38. Sun H-Q, Kwiatkowska K, Wooten DC, Yin HL. Effects of CapG overexpression on agonist-induced motility and second messenger generation. J Cell Biol 1995; 129: 147-56.
39. Pollard TD, Borisy GG. Cellular motility driven by assembly and disassembly of actin filaments. Cell 2003; 112: 453-65.
40. Hirsch DS, Pirone DM, Burbelo PD. A new family of Cdc42 effector proteins, CEPs, function in fibroblast and epithelial cell shape change. J Biol Chem 2001; 276: 875-83.
41. Li J, Aderem A. MacMARCKS, a novel member of the MARCKS family of protein kinase C substrates. Cell 1992; 70: 791-801.
42. Kurochkin IV, Yonemitsu N, Funahashi SINH. ALEX1, a novel human armadillo repeat protein that is expressed differentially in normal tissues and carcinomas. Biochem Biophys Res Commun 2003; 280: 340-7.
43. Pestonjamasp KN, Pope RK, Wulfkuhle JD, Luna EJ. Supervillin (p205): A novel membrane-associated, F-Actin-binding protein in the Villin/Gelsolin superfamily. J Cell Biol 1997; 139: 1255-69.
44. Masuda M, Yageta M, Fukuhara H et al. The tumor suppressor protein TSLC1 is involved in cell-cell adhesion. J Biol Chem 2002; 277: 31014-9.
45. Olive M, Krylov D, Echlin DR et al. A dominant negative to activation protein-1 (AP1) that abolishes DNA binding and inhibits oncogenesis. J Biol Chem 1997; 272: 18586-94.
46. Rutberg SE, Adams TL, Glick A et al. Activator protein 1 transcription factors are fundamental to v-rasHa- induced changes in gene expression in neoplastic keratinocytes. Cancer Res 2000; 60: 6332-8.
47. Alani R, Brown P, Binetruy B et al. The transactivating domain of c-Jun is required for cotransformation of rat embryo cells. Mol Cell Biol 1991; 11: 6286-95.
48. Kwiatkowski DJ. Functions of Gelsolin: Motility, signaling, apoptosis, cancer. Cur Op Cell Biol 1999; 11: 103-8.
49. Witke W, Li W, Kwiatkowski DJ, Southwick FK. Comparison of CapG and gelsolin-null macrophages: Demonstration of a unique uole for CapG in ueceptor-mediated ruffeling, phagocytosis, and vesicle rocketing. J Cell Biol 2001; 154: 775-84.
50. ink4a and p52. Mol Cell Biol 2003; 24: 1540-59.